“
has reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid (lenalidomide capsules) in the US,” the drug major said in a media release.
Shares of Sun Pharma jumped over one per cent to Rs 679.60 on Tuesday. The counter was trading flat at Rs 672.25 at 9.55 am. BSE Sensex was trading 402.66 points or 0.77 per cent higher at 52,977.11 at the same time. The scrip settled at Rs 671.25 on Monday.
Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a licence to Celgene’s patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022.
The Pharma major has underperformer BSE Sensex in the last one year. The counter has rallied 36 per cent, whereas the benchmark Index is up by 52 per cent during the period under review.
As a result of the settlement, all Hatch-Waxman litigation between Sun Pharma and Celgene, regarding the Revlimid patents, will be dismissed. Additional details regarding the settlement are confidential. The agreement is subject to customary regulatory approvals, the company said.
